Skip to main content
Equibles

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC

Position in BBIO — BridgeBio Pharma, Inc.

CIK 1638555 Boston, MA
Back to BBIO Full portfolio

Position in BBIO

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$46,261,390
+$20,060,160 QoQ
Shares Held
621,125
+76.0% QoQ
Ownership
0.318%
of shares outstanding
% of Portfolio
1.20%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
6 quarters on record
Voting authority Sole 73% Shared 0% None 27%

Common Shares in BBIO Over Time

Shares Held

Position Value (USD)

Derivatives in BBIO

reported options exposure · as of Mar 31, 2026
CallValue
$0
CallShares
0
PutValue
$11,139,000
PutShares
150,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds $293,644,011 across 5 Biotechnology names. BBIO ranks #5 (15.8% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ARWR
Arrowhead Pharmaceuticals, Inc.
 830,247 $67,673,432
2 ORKA
Oruka Therapeutics, Inc.
 658,301 $62,650,506
3 IONS
Ionis Pharmaceuticals Inc
 787,263 $62,422,083
4 ABVX
Abivax S.A.
 410,000 $54,636,600
5 BBIO
BridgeBio Pharma, Inc.
This page 		621,125 $46,261,390

All Filings in BBIO

Export CSV
7 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $46,261,390 621,125
2026-03-31 $11,139,000 150,000
2026-03-31 $26,201,230 352,831
2025-12-31 $62,247,103 813,794
2025-09-30 $41,900,517 806,710
2025-06-30 $32,719,429 757,745
2025-03-31 $39,049,995 1,129,592